UK patient groups say that pharma could be more transparent

An independent study of the views of 83 UK-based patient groups on the corporate reputation of 15 pharmaceutical companies, and of the pharma industry as a whole, reported a lack of transparency at sharing clinical data. The study was conducted by PatientView, and collected the opinions of patient groups in a survey conducted between November […]

read more

Kidney cancer vaccine abandoned after failure of phase 3 clinical trial

Argos Therapeutics has abandoned its phase 3 trial of rocapuldencel-T (a kidney cancer vaccine) in combination with sunitinib in patients with newly diagnosed metastatic renal cell carcinoma (mRCC) due to lack of efficacy. Last year, an independent data monitoring committee (IDMC) recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the first-line treatment of mRCC be stopped because […]

read more

FDA grants fast track designation to glutaminase inhibitor CB-839 in combination with cabozantinib for metastatic kidney cancer

Calithera Biosciences announced earlier this week that the US Food and Drug Administration (FDA) has granted fast track designation to CB-839 for use in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma (RCC) who received one or two prior courses of treatment (including at least one TKI). Fast track designation by the FDA […]

read more

Kidney cancer may begin to develop in childhood

Scientists working on a Cancer Research UK funded study have discovered that the development of kidney cancer follows distinct paths, which can begin in childhood. These evolutionary paths enable scientists to detect whether a tumour will be aggressive and spread. “We could use these rules to help choose the best treatments, and potentially to diagnose some […]

read more

Axitinib fails as an adjuvant therapy for high risk kidney cancer

The phase 3 ATLAS clinical trial to assess axitinib as an adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy has been stopped early. An interim analysis showed that it was highly unlikely that axitinib would offer any benefit for these patients. The interim analysis failed to demonstrate a […]

read more
Showing 1 to 6 of 357 results